SCHEMBL3883339

SCHEMBL3883339

[CH2]C(C)CCCCCC(C)C

nearest known ligand 0.50

Predicted protein targets (top 14)

geneUniProtsupporting neighboursconfidence
LMNA P02545 1/20 0.50
KDM4C Q9H3R0 2/20 0.32
KDM4A O75164 1/20 0.32
PHF8 Q9UPP1 1/20 0.32
KDM2A Q9Y2K7 1/20 0.32
TRPV1 Q8NER1 1/20 0.32
TRPA1 O75762 1/20 0.32
MEN1 O00255 1/20 0.31
CYP3A4 P08684 1/20 0.31
ALOX15 P16050 1/20 0.31
KMT2A Q03164 1/20 0.31
BLM P54132 1/20 0.31
HIF1A Q16665 1/20 0.31
EPAS1 Q99814 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3267924 1.00 LMNA (0.50) LMNAKDM4CKDM4APHF8KDM2A
SCHEMBL28419560 1.00 LMNA (0.50) LMNAKDM4CKDM4APHF8KDM2A
SCHEMBL29183000 1.00 LMNA (0.50) LMNAKDM4CKDM4APHF8KDM2A
SCHEMBL20335504 1.00 LMNA (0.50) LMNAKDM4CKDM4APHF8KDM2A
SCHEMBL11720335 1.00 LMNA (0.50) LMNAKDM4CKDM4APHF8KDM2A
SCHEMBL28851724 0.97 LMNA (0.48) LMNAKDM4CKDM4APHF8KDM2A
SCHEMBL1282483 0.97 LMNA (0.53) LMNAMEN1CYP3A4ALOX15KMT2A
SCHEMBL9122712 0.90
SCHEMBL446676 0.90
SCHEMBL7008843 0.90 TRPV1 (0.36) LMNATRPV1TRPA1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10955421-B2 Detection of membrane proteins OXFORD UNIVERSITY INNOVATION LIMITED (GB) 2021-03-23 US claimed
US-20200240997-A1 DETECTION OF MEMBRANE PROTEINS OXFORD UNIVERSITY INNOVATION LIMITED (GB) 2020-07-30 US claimed
WO-2018154318-A1 DETECTION OF MEMBRANE PROTEINS OXFORD UNIVERSITY INNOVATION LIMITED (GB) 2018-08-30 WO claimed
US-10955421-B2 Detection of membrane proteins OXFORD UNIVERSITY INNOVATION LIMITED (GB) 2021-03-23 US disclosed
EP-3194371-B1 ANTIMICROBIAL IMIDAZOLIUM COMPOUNDS AGENCY SCIENCE TECH & RES (SG) 2020-09-02 EP disclosed
CN-107108518-B Antibacterial imidazolium compounds 新加坡科技研究局 2020-08-11 CN disclosed
US-20200240997-A1 DETECTION OF MEMBRANE PROTEINS OXFORD UNIVERSITY INNOVATION LIMITED (GB) 2020-07-30 US disclosed
US-10570097-B2 Antimicrobial imidazolium compounds AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH (SG) 2020-02-25 US disclosed
US-20190016684-A1 ANTIMICROBIAL IMIDAZOLIUM COMPOUNDS AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH (SG) 2019-01-17 US disclosed
US-10160728-B2 Antimicrobial imidazolium compounds AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH (SG) 2018-12-25 US disclosed
WO-2018154318-A1 DETECTION OF MEMBRANE PROTEINS OXFORD UNIVERSITY INNOVATION LIMITED (GB) 2018-08-30 WO disclosed
CN-107108518-A Antibacterial imidazolium compounds 新加坡科技研究局 2017-08-29 CN disclosed
EP-3194371-A1 ANTIMICROBIAL IMIDAZOLIUM COMPOUNDS Agency for Science, Technology and Research (SG) 2017-07-26 EP disclosed
CN-106831408-A A kind of 2,8- dimethyl azelaic acid, its synthetic method and application 江苏国泰超威新材料有限公司 2017-06-13 CN disclosed
WO-2016043660-A1 ANTIMICROBIAL IMIDAZOLIUM COMPOUNDS AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH (SG) 2016-03-24 WO disclosed
US-20090149584-A1 USE OF HEXAHYDROPHTHALIMIDE COMBINATIONS AS SOFTENER BASF AKTIENGESELLSCHAFT (DE) 2009-06-11 US disclosed
CN-101426843-A Use of hexahydrophthalimide combinations as softener BASF SE (DE) 2009-05-06 CN disclosed
EP-2013278-A1 USE OF HEXAHYDROPHTHALIMIDE COMBINATIONS AS SOFTENER BASF SE (DE) 2009-01-14 EP disclosed
WO-2008006834-A2 USE OF IMIDAZOLE COMPOUNDS AS PLASTICISERS BASF SE (DE) 2008-01-17 WO disclosed
WO-2007122204-A1 USE OF HEXAHYDROPHTHALIMIDE COMBINATIONS AS SOFTENER BASF SE (DE) 2007-11-01 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10570097-B2 Antimicrobial imidazolium compounds CCNI, MACF1, ECI1 LMNA 1163/4885KDM4C 4120/4885KDM4A 4679/4885
US-10160728-B2 Antimicrobial imidazolium compounds CCNI, MACF1, ECI1 LMNA 1163/4885KDM4C 4120/4885KDM4A 4679/4885
US-20200240997-A1 DETECTION OF MEMBRANE PROTEINS CETP, VAPA, PCTP LMNA 1166/4885KDM4C 4358/4885KDM4A 3444/4885
US-20190016684-A1 ANTIMICROBIAL IMIDAZOLIUM COMPOUNDS CCNI, MACF1, ECI1 LMNA 1163/4885KDM4C 4120/4885KDM4A 4679/4885
US-10955421-B2 Detection of membrane proteins CETP, VAPA, PCTP LMNA 1166/4885KDM4C 4358/4885KDM4A 3444/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.